Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...
Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...
Pfungstadt (ots) - - Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARS-CoV-2 virus in human cells. - The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells. - Preclinical testing of this compound has ...
